Biomarker Predicts Nonresponse to CAR T in Pediatric ALL

Alternative strategies could be offered to children and young adults with advanced acute lymphoblastic leukemia (ALL) identified as being unlikely to respond to the expensive therapy.

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Washington ,New Jersey ,Seattle ,American ,Javed Khan ,Maria Lopez ,Katherinee Masih ,Jefferson Health New Jersey ,National Cancer Institute ,Sidney Kimmel Cancer Center ,Genetics Branch ,Cancer Research ,American Association For Cancer Research ,Baldrick Foundation ,Seattle Children Research Institute ,Cambridge Scholars Program ,American Association ,Annual Meeting ,Ana Maria Lopez ,Washington Township ,Seattle Children ,Transposase Accessible Chromatin ,Research Institute ,Strong Against Cancer ,Lemonade Stand ,Cambridge Scholars ,Acute Leukemia ,Biologic Therapy ,Chimeric Antigen Receptort Cell Therapy ,Chimeric Antigen Receptors ,Himeric Immunoreceptors ,Himerict Cell Receptors ,Rtificialt Cell Receptors ,Ar T ,Precision Medicine ,Hematology ,Leukemia ,Biomarker ,Iological Marker ,Oncological Medicine ,Transplantation Stem Cell ,Ransplantation Hematopoietic Stem Cell ,Hematopoietic Stem Cell Transplantation ,Tem Cel ,